secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001558370-23-005188
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path reports FY2022 net loss of $13.9M ($1.91/share); cash drops to $10.4M
------------------------------------------------------------------------------

- Net loss $13.9M ($1.91 per share) vs $10.4M ($1.55) in 2021; R&D expense rose to $9.2M.
- Cash at Dec 31, 2022 was $10.4M, down from $23.8M; operating cash burn of $15.1M.
- First patient dosed in Phase 1/1b trial of BP1001-A in solid tumors (ovarian, pancreatic, breast).
- Phase 2 prexigebersen AML trial: two cohorts exceeded minimum efficacy; interim analyses expected Q2 2023.
- BP1002 Phase 1/1b in relapsed/refractory AML: initial cohort data readout expected Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837023005188/0001558370-23-005188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837023005188/bpth-20230331x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-005188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer